gilead solid first quarter driven hiv maintain
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research may
estim apr
price data apr
rate updat apr
currenc amount express
methodolog valu compani
maintain fair valu estim gilead
follow solid first-quart result firm hiv
portfolio grew billion drive overal
product sale growth billion first quarter like
strongest year million revenu
pull forward unit state europ due hiv
patient stock take advantag refil
start coronaviru pandem like revers
subsequ quarter expect fewer new patient
move onto hiv treatment prevent regimen
begin second quarter patient delay offic
visit physician slower switch prevent
truvada see gener competit fourth
quarter descovi howev hiv prevent
patient alreadi use descovi signific
improv end fourth quarter
within sight firm goal end
third quarter also expect sale cell therapi
yescarta slow treatment center reduc access
pandem overal think gilead
infecti diseas portfolio still signific stay
power support wide moat thank solid uptak
product like biktarvi descovi long-act hiv
treatment pipelin think firm still build
critic mass immunolog filgotinib could launch
arthriti second half year oncolog
pipelin beyond cell therapi ad
develop manufactur cost valuat
model remdesivir continu think drug could
see signific sale potenti next year initi
donat suppli exhaust
discuss april note rais
probabl approv therapi remdesivir
follow solid data gilead simpl studi
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
develop market therapi treat life-threaten
infecti diseas core portfolio focus hiv
hepat acquisit coru pharma myogen cv
therapeut arresto bioscienc calistoga broaden focu
includ pulmonari cardiovascular diseas cancer gilead
acquisit pharmasset brought right hepat drug sovaldi
also part combin drug harvoni kite acquisit
pend forty-seven acquisit boost gilead exposur cell therapi
non-cel therapi oncolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
sever ill patient well niaid placebo-
control studi spectrum hospit patient
think food drug administr fda
grant emerg use author eua immin
full fda approv follow mid-year still
await data gilead studi moder patient
late may well detail niaid studi could
show us particular subset patient
signific impact remdesivir treatment
think remdesivir efficaci creat bar
success regimen expect see
combin studi begin includ niaid plan
combin remdesivir baricitinib lilli jak
inhibitor market olumi think
abl produc data june manag note could
spend billion develop remdesivir
provid revenu outlook say
initi suppli cours roughli doubl
five-day dose effect simpl studi
donat expect initi use broad
among hospit patient data moder
studi hospit patient oxygen therapi
posit gilead addit formul plan --
subcutan inhal dose -- could provid treatment
option outsid hospit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
